Last reviewed · How we verify
GADOFOSVESET
At a glance
| Generic name | GADOFOSVESET |
|---|---|
| Sponsor | Lantheus Medcl |
| Drug class | Paramagnetic Contrast Agent |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
Common side effects
- Pruritis
- Headache
- Nausea
- Vasodilatation
- Paresthesia
- Injection site bruising
- Dysgeusia
- Burning sensation
- Venipuncture site bruise
- Hypertension
- Dizziness
- Feeling cold
Serious adverse events
- Anaphylaxis
- Anaphylactoid reactions
Key clinical trials
- Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases (PHASE2)
- Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent (PHASE3)
- Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease (PHASE4)
- Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
- Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) (PHASE4)
- Gadofosveset Trisodium for Heart Imaging Studies
- Imaging of Totally Blocked Arteries (PHASE1)
- Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GADOFOSVESET CI brief — competitive landscape report
- GADOFOSVESET updates RSS · CI watch RSS
- Lantheus Medcl portfolio CI